Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)

NCT01191008 is registered in ClinicalTrials.gov with Pfizer's Upjohn has merged with Mylan to form Viatris Inc. as lead sponsor.

NCT NCT01191008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01191008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Special Investigation Of Long Term Use Of Xalacom(Regulatory Post Marketing Commitment Plan)
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase
Observational
Overall status
Completed
Start date
October 31, 2010
Completion date
May 31, 2015
Enrollment
661 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

glaucoma, ocular hypertension